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BACKGROUND: a-Fetoprotein (AFP) is a tumour-associated antigen in hepatocellular carcinoma (HCC) and is a target for
immunotherapy. However, there is little information on the pattern of CD4 (Th1) and CD8 (Tc1) T-cell response to AFP in patients
with HCC and their association with the clinical characteristics of patients.
METHODS: We therefore analysed CD4 and CD8 T-cell responses to a panel of AFP-derived peptides in a total of 31 HCC patients
and 14 controls, using an intracellular cytokine assay for IFN-g.
RESULTS:Anti-AFP Tc1 responses were detected in 28.5% of controls, as well as in 25% of HCC patients with Okuda I (early tumour
stage) and in 31.6% of HCC patients with stage II or III (late tumour stages). An anti-AFP Th1 response was detected only in HCC
patients (58.3% with Okuda stage I tumours and 15.8% with Okuda stage II or III tumours). Anti-AFP Th1 response was mainly
detected in HCC patients who had normal or mildly elevated serum AFP concentrations (P¼0.00188), whereas there was no
significant difference between serum AFP concentrations in these patients and the presence of an anti-AFP Tc1 response. A Th1
response was detected in 44% of HCC patients with a Child–Pugh A score (early stage of cirrhosis), whereas this was detected in
only 15% with a B or C score (late-stage cirrhosis). In contrast, a Tc1 response was detected in 17% of HCC patients with a Child–
Pugh A score and in 46% with a B or C score.
CONCLUSION:These results suggest that anti-AFP Th1 responses are more likely to be present in patients who are in an early stage of
disease (for both tumour stage and liver cirrhosis), whereas anti-AFP Tc1 responses are more likely to be present in patients with
late-stage liver cirrhosis. Therefore, these data provide valuable information for the design of vaccination strategies against HCC.
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Hepatocellular carcinoma (HCC) overexpresses several tumour-
associated antigens (Kittaka et al, 2008). Some of these antigens,
such as MAGE, Glypican-3 and NY-ESO-1, are also expressed by
many other types of cancer cells (Shang et al, 2004; Capurro and
Filmus, 2005), whereas a-fetoprotein (AFP) is specific to HCC and
testicular carcinoma. The synthesis of AFP decreases dramatically
after birth and only trace amounts are expressed in the adult liver.
During liver regeneration and hepatocarcinogenesis, expression of
the AFP gene is reactivated in adults (Cooper et al, 2001;
Mizejewski, 2007), with the majority of HCC patients showing an
increase in serum AFP levels. The induction of an anti-AFP cell-
mediated immune response can control tumour growth in animal
models (Grimm et al, 2000). In humans, it has been shown that B
and T cells can recognise peptide epitopes within the AFP sequence
and can develop into effector and/or regulatory lymphocytes.
Several AFP-derived HLA class I (HLA-A2 and HLA-A24) and class
II (HLA-DR) restricted CD4 (Th1) and CD8 (Tc1) epitopes have
been identified (Bei et al, 1999; Butterfield et al, 1999, 2001; Meng
et al, 2000; Alisa et al, 2005, 2008; Mizukoshi et al, 2005; Liu et al,
2006; Ayaru et al, 2007). The results from several studies show
that the detection of AFP-specific CD8 T cells is restricted to
HCC patients, but does not correlate with elevated serum AFP
concentrations, vascular invasion or type of viral infection (Ritter
et al, 2004; Butterfield et al, 2007; Thimme et al, 2008). In contrast,
we have shown that CD4 T-cell responses to an immunodominant
AFP-derived peptide are only detectable in HCC patients, and this
response is mainly detected in patients with low serum AFP
concentrations and early-stage disease (Alisa et al, 2005). To
address these conflicting results, we analysed Th1 and Tc1
responses in parallel in the same group of patients/controls. Our
findings demonstrate that a Th1 response is only detectable in HCC
patients, whereas a Tc1 response is detectable in both HCC and
controls. Moreover, these results suggest that anti-AFP Th1
responses are more likely to be present in an early tumour stage
or liver cirrhosis, whereas anti-AFP Tc1 responses are more likely
to be present in patients with more severe liver cirrhosis.
MATERIALS AND METHODS
Synthetic peptides
Peptides corresponding to the sequence of AFP were purchased
from Mimotopes Pty Ltd. (Clayton Victoria, Australia).
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This study was approved by ethical committees and all patients
gave written informed consent. Peripheral blood mononuclear
cells (PBMCs) were isolated from the blood of patients with HCC
or from healthy donors.
Expansion of T cells in vitro
The RPMI 1640 medium, MEM medium, penicillin and strepto-
mycin and 10% heat-inactivated FCS were purchased from Life
Technologies (Grand Island, NY, USA). T-cell lines were generated
as described previously (Alisa et al, 2005). In brief, PBMCs were
re-suspended at a concentration of 1.5 10
6 per ml in MEM, 10% FCS
(Life Technologies), and stimulated with individual peptides (1mM)
or peptide pools in 96-well plates. Recombinant IL-2 (50IUml
 1)
was added on day 3 of culture, and cells were analysed after a total
of 10–12 days of culture.
Intracellular IFN-c staining
Expanded T cells were incubated for 5h at 371Ca t1 106 cells per
ml in MEM, 10% FCS with AFP-derived peptides (1mM) and in the
presence of Brefeldin A (10mgml
 1 Sigma-Aldrich, St Louis, MO,
USA). Cells were surface stained with Cy-chrome-conjugated anti-
CD4 or anti-CD8 antibodies (BD PharMingen, Cowley, UK). The
cells were then fixed and permeabilised using Cytofix/Cytoperm
(BD PharMingen), and stained for intracellular cytokines with
FITC-conjugated anti-IFNg or isotype control (R&D Systems,
Abingdon, UK), washed twice and analysed by flow cytometry. The
expansion of T cells did not induce non-specific (no peptide) IFN-
g-producing T cells and all background levels (no peptide or
irrelevant peptide) were between 0.1 and 0.5%. An immunological
response/responder was defined as a five-fold increase in the
frequency of cytokine-producing cells above control peptides/no
peptide.
AFP measurement
Concentrations of serum AFP were measured using a microparticle
enzyme immunoassay kit obtained from Abbott Laboratories (Abbott
Park, IL, USA) and carried out according to the manufacturer’s
instructions. In brief, anti-AFP microparticles were incubated with
the blood specimen, and an aliquot of the reaction mixture was
transferred to the matrix cell. The matrix cell was washed, and the
anti-AFP conjugate was added to it. The substrate was then added to
the matrix cell and the fluorescent product was measured by the
microparticle enzyme immunoassay optical assembly.
Statistical analysis
The Mann–Whitney U-test was used to compare the concentration
of serum AFP in HCC patients and the ability of T cells to respond
to the identified epitope (responder vs non-responder). The w
2 test
was used to compare whether the percentage of CD4 T-cell
responders was predominantly in patients with Okuda tumour
stage I or IIþIII. Statistical significance was defined as Pp0.05.
RESULTS
An anti-AFP Tc1 response was detected in controls and
HCC patients, whereas an anti-AFP Th1 response was
detected only in HCC patients
Peripheral blood mononuclear cells were isolated from a total of 31
patients with HCC (HCC01-HCC31), from 8 patients with cirrhosis
(LC01-08) and from 6 healthy individuals (NC01-06) (Tables 1 and 2).
Table 1 Hepatocellular carcinoma (HCC) patients evaluated in this study
Sample ID Gender Age (years) Cirrhosis Tumour Hepatitis Okuda
a AFP (ngml
 1) Child–Pugh
HCC01 M 62 + Multifocal HCV III 180 B
HCC02 M 62 + Single HCV I 8 A
HCC03 M 60 + Single HBV/HCV II 200 B
HCC04 M 53 + Single HBV/HCV II 37 B
HCC05 M 63 + Multifocal HCV I 64 A
HCC06 M 66 + Multifocal HCV I 32 A
HCC07 M 66 + Multifocal HCV I 10 A
HCC08 M 55 + Multifocal — II 145 C
HCC09 M 66 + Multifocal HBV I 8 A
HCC10 M 52 + Single HBV II 48 B
HCC11 M 55   Multifocal — I 60 A
HCC12 M 63 + Diffuse — I 13077 A
HCC13 M 35 + Multifocal HBV/HCV III 96730 B
HCC14 M 59 + Single — I 41930 A
HCC15 F 32 + Multifocal HBV II 31 A
HCC16 F 58 + Multifocal HBV/HCV I 14 A
HCC17 M 67 + Multifocal HBV II 10 A
HCC18 M 32 + Multifocal — I 8 A
HCC19 F 71 + Multifocal HBV II 813500 A
HCC20 M 79 + Multifocal HCV III 70 C
HCC21 M 61 - Diffuse HCV II 1234 B
HCC22 M 61 + Multifocal — III 5 C
HCC23 M 62 + Multifocal HBV/HCV II 1501 B
HCC24 M 67 + Diffuse HBV II 188 A
HCC25 M 84 + Single HCV/HBV I 1 A
HCC26 F 67 + Diffuse HBV II 12432 B
HCC27 M 62 + Single HBV/HCV II 165 C
HCC28 F 46 + Single HBV/HCV II 10 A
HCC29 M 54 + Single HCV II 14 B
HCC30 M 53 + Multifocal HCV II 157 A
HCC31 M 58 + Multifocal HCV I 108 A
Abbreviations: AFP¼a-fetoprotein; F¼female; HBV¼Hepatitis B virus; HCV¼Hepatitis C virus; M¼male.
aOkuda is clinical staging systems for hepatocellular carcinoma.
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peptide pools (Supplementary Table 1). The reactivity of T-cell
lines to relevant and irrelevant peptide pools was analysed using an
intracellular cytokine assay for IFN-g after 10–12 days of culture
(Figure 1A). An anti-AFP CD4 T-cell response was detected in 32%
of HCC patients (10 out of 31), whereas no CD4 T-cell response
was detected in controls. In contrast, an anti-AFP CD8 T-cell
response was detected in 29% of HCC patients (9 out of 31) and in
29% of the control group (4 out of 14, Figure 1B). The presence of
both a CD4 and a CD8 T-cell response to AFP peptides was
detected in three HCC patients (Figure 1C).
To determine the reacting peptide(s) within the peptide pools,
expanded T cells were treated with individual peptides of the
reacting pools, and peptide-specific intracellular IFN-g production
by CD4 and CD8 T cells was analysed using flow cytometry
(Figure 2). Among the responders, PBMCs were available from
LC01, LC03, NC02, HCC06, HCC20 and HCC25 for further studies.
Dot plots of anti-AFP-specific IFN-g-producing CD4 or CD8 T cells
from these individuals are shown (Supplementary Figures 1 and 2).
These results suggest that Th1 and Tc1 responses are multi-
specific.
Anti-AFP Th1 responses are mainly detected in an early
tumour stage
An AFP-specific CD4 T-cell response was mainly detected in HCC
patients with normal or mildly elevated serum AFP (P¼0.0188,
Mann–Whitney U-test). In contrast, there was no significant
difference in AFP concentrations between CD8 T-cell responders
and non-responders (Figure 3A–C). Median serum AFP concen-
trations were 7.5-fold higher in HCC patients who lacked a CD4
T-cell response (non-responders) than in those who had a CD4
T-cell response (responders) (Figure 3B). There was also a significant
difference in the number of patients with Okuda tumour stage I vs
those with stage II or III in CD4 T-cell responders (w
2, P¼0.04;
95% confidence intervals), whereas there was no difference in the
number of patients with Okuda tumour stage I vs stage II or III in
CD8 or total T-cell responders. This indicates that patients in stage
II or III are significantly less likely to have an anti-AFP Th1
response, whereas anti-AFP Tc1 responses remain unchanged.
Overall, the results demonstrate that CD8 T-cell responses to
AFP are detectable in control groups (28.5%), as well as in Okuda
Table 2 Clinical characteristics of the controls
Variables All controls (n¼14)
Patients with liver cirrhosis n¼8
Median age (years) 56.5 (34–75)
Patients with HCV or HBV/others 4/4
Median AFP (ngml
 1) 9.5 (4–11)
Healthy donors n¼6
Median age (years) 35.8 (23–42)
AFP (ngml
 1) Unknown
Abbreviations: AFP¼a-fetoprotein; HBV¼Hepatitis B virus; HCV¼Hepatitis C
virus.
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Figure 1 Anti-AFP CD4 T-cell responses are only detected in HCC patients. (A) Peptide-specific intracellular IFN-g production by CD4 and CD8 T cells
was determined using flow cytometry. Representatives of CD4 and CD8 T-cell responses against AFP-derived peptides are shown. (B) The percentages of
HCC patients or controls with CD4 or/and CD8 T cells reacting to AFP-derived peptides are shown. (C) The number of HCC patients with or without anti-
AFP CD4, CD8 and CD4 and CD8 T-cell responses is presented.
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stumour stage I HCC patients (25%) and Okuda tumour stage
IIþIII HCC patients (31.6%). In contrast, AFP-specific CD4 T-cell
responses are only detected in HCC patients and response was
mainly detected in Okuda tumour stage I HCC patients (58.3%)
and to a lesser extent in Okuda tumour stage II or III HCC patients
(15.8%) (Figure 4B).
8
6
4
2
0
2.0
1.5
1.0
0.5
0.0
LC01
HCC06 HCC20 HCC20
HCC25 HCC25
LC03 NC02 4
3
2
1
0
15
10
5
0
20
15
10
5
0
5
4
3
2
1
0
8
6
4
2
0
3
2
1
0
No peptide
1–9
277–285
347–355
447–455
548–556
No peptide
343–351
364–373
489–497
570–578
No peptide
4–12
47–55
235–243
453–461
410–418
No peptide
87–95
140–148
174–182
492–500
485–493
No peptide
343–351
364–373
546–554
570–578
No peptide
343–351
364–373
489–497
546–554
No peptide
35–43
447–455
545–553
548–556
No peptide
86–95
249–258
475–484
%
 
C
D
8
+
 
I
F
N
-

 
+
 
c
e
l
l
s
%
 
C
D
4
+
 
I
F
N
-

+
 
c
e
l
l
s
%
 
C
D
4
+
 
I
F
N
-

+
 
c
e
l
l
s
%
 
C
D
8
+
 
I
F
N
-

+
 
c
e
l
l
s
%
 
C
D
4
+
 
I
F
N
-

+
 
c
e
l
l
s
%
 
C
D
8
+
 
I
F
N
-

+
 
c
e
l
l
s
%
 
C
D
8
+
 
I
F
N
-

 
+
 
c
e
l
l
s
%
 
C
D
8
+
 
I
F
N
-

+
 
c
e
l
l
s
Figure 2 Multi-specific CD4 and CD8 T-cell responses in HCC patients and controls. Expanded T cells were incubated with indicated AFP peptides and
peptide-specific intracellular IFNg was analysed using flow cytometry. Naturally occurring CD4 and CD8 T-cell responses against individual AFP-derived
peptides were analysed in three patients with HCC and in three controls. The percentages of peptide-specific CD4 (black) or CD8 (grey) T-cell responses
to individual peptides are shown.
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Figure 3 HCC patients with anti-AFP CD4 T-cells responses have significantly lower levels of serum AFP. Serum AFP levels in HCC patients with or
without (A) anti-AFP total T-cells responses (both CD4 and CD8), (B) CD4 T-cell responses or (C) CD8 T-cell responses are shown. Anti-AFP CD4 T-cell
response was detected in patients with low or moderately elevated serum AFP (n¼0.018). Median of serum AFP levels for responders and non-responders
are presented and each dot represents a patient with HCC.
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switches to an anti-AFP Tc1 response as liver cirrhosis
progresses
Child–Pugh grading is the most commonly used method to
evaluate liver cirrhosis and liver function in HCC patients, and is
used to assess prognosis, evaluate the required strength of
treatment required and determine the necessity for surgical
intervention. Of the 31 HCC patients assessed, 18 were classified
as having a Child–Pugh A score and 13 patients were classified as
having a Child–Pugh B or C score. We analysed the presence of
AFP-specific CD4 and CD8 T-cell responses in HCC patients with
these different Child–Pugh scores. Just over 44% of HCC patients
with a Child–Pugh A score had a CD4 T-cell response (8 out of
18), whereas only 15% of HCC patients with a Child–Pugh B or C
score had as CD4 T-cell response (2 out of 13), suggesting that an
AFP-specific Th1 response is mainly detected in HCC patients with
a Child–Pugh A score (Figure 5). A CD8 T-cell response was
detected in 17% of HCC patients with a Child–Pugh A score (3 out
of 18), and in 46% of HCC patients with a Child–Pugh B or C score
(6 out of 13, Figure 5). These results suggest that, in contrast to a
Th1 response, a Tc1 response is mainly detected in HCC patients
with a Child–Pugh B or C score. However, total T-cell response
(CD4 and CD8) was detected in 50 (9 out of 18) and 53% (7 out of
13) of HCC patients with a Child–Pugh A score and a Child–Pugh
BþC score, respectively. Taken together, these results suggest that
the balance between anti-AFP Th1 and Tc1 responses switches to
an anti-AFP Tc1 response as liver cirrhosis progresses.
DISCUSSION
There are contrasting reports on the presence of anti-AFP T-cell
responses and their association with clinical characteristics of
patients, such as serum AFP concentration and the stage of disease
in HCC patients (Ritter et al, 2004; Alisa et al, 2005; Ayaru et al,
2007; Butterfield et al, 2007; Evdokimova et al, 2007; Thimme et al,
2008). We hypothesised that these contrasting reports may be due
to a difference in the presence of anti-AFP CD4 and CD8 T-cell
responses over the course of disease. A concomitant analysis of
anti-AFP CD4 and CD8 T-cell responses in the same group of
patients showed that anti-AFP CD4 T-cell responses are present in
HCC patients but not in controls, whereas anti-AFP CD8 T-cell
responses are present in both HCC patients and controls. CD4
T cells from HCC patients reacted to a wide range of peptide pools,
suggesting that the anti-AFP CD4 T-cell response is multi-specific
(data not shown). However, owing to the limited number of cells
isolated from HCC patients, we were unable to analyse the
responses to individual peptides in all patients with a T-cell
response. For the same reason, we were also unable to analyse the
ex vivo responses in these groups of patients. However, we have
previously reported that AFP-specific CD4 T-cell responses are not
detectable ex vivo (Ayaru et al, 2007).
In this study, we used a panel of 9–10-mer peptides that are
normally expected to bind to MHC class I molecules. However, we
showed that 10 mer AFP-derived peptides can also be presented by
MHC class II molecules, and that CD4 T cells could respond
equally well to 14- or 10-mer peptides and produce IFN-g (Alisa
et al, 2005). AFP-specific Th1 cells may produce IFN-g, IL-2 and
TNF-a (Alisa et al, 2005). Interleukin-2 is often associated with a
memory response, and it can be produced by both antigen-specific
CD4 and CD8 T cells. In our experience, not all AFP-specific IFN-g
producing T cells produced detectable intracellular IL-2. Thus, we
decided to analyse the expansion of antigen-specific Th1 cells that
are characterised by IFN-g production.
It has been suggested that healthy donors have a weak response
to the whole AFP protein and this response is only detectable when
the antigen is presented by dendritic cells (DCs) (Evdokimova
et al, 2007). The presentation of peptide epitopes to T cells by DCs
has been shown to amplify the underlying response and improve
the sensitivity of assays (Whelan et al, 2009). This indicates that a
weak anti-AFP Th1 response is present in healthy donors and that
the detection of this response would require professional antigen-
presenting cells. Accordingly, we were able to detect IFN-g-
producing AFP-specific CD8 T cells in healthy donors. In contrast
to our finding, Mizukoshi et al (2005) were unable to detect this
response in healthy donors. This discrepancy could be explained
by the methods used in different studies, with ex vivo assays
detecting effector and expanded T cells detecting memory
populations. Furthermore, a comprehensive and careful analysis
of anti-AFP CD8 T-cell responses by Thimme et al (2008)
demonstrated that anti-AFP CD8 T-cell responses are detectable
in controls and in HCC patients (Thimme et al, 2008).
The results from several studies support the fact that the
presence of AFP-specific CD8 T cells does not correlate with
clinical features of disease such as elevated serum AFP concentra-
tions (Ritter et al, 2004; Butterfield et al, 2007; Thimme et al, 2008).
Moreover, no association has been observed between the
concentration of serum AFP in HCC patients and the presence of
CD8 T-cell responses to non-AFP tumour-associated antigens,
such as NY-ESO-1 (Gehring et al, 2009). Our results support these
findings and demonstrate that anti-AFP Tc1 responses are detected
in all groups of patients. In contrast, anti-AFP Th1 responses are
more likely to be detected in HCC patients in an early stage of
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Figure 4 Anti-AFP CD4 T-cell response is more likely to be detected in
HCC patients with early stage of disease. (A) The percentages of anti-AFP
T-cell response (both CD4 and CD8), CD4 T-cell response or CD8 T-cell
response are shown in HCC patients with different stage of disease (Okuda
I vs Okuda IIþIII). (B) The percentages of anti-AFP CD4 or CD8 T-cell
responses in controls, HCC patients with Okuda I and HCC patients with
Okuda IIþIII are shown.
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Figure 5 Th1 response is mainly detected in HCC patients with Child–
Pugh A grading. The percentages of anti-AFP T-cell response (both CD4
and CD8), CD4 T-cell response or CD8 T-cell response are shown in
HCC patients with different Child–Pugh scores (A or BþC).
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low. This suggests that there is a difference in the activation of
anti-AFP CD4 vs CD8 T cells in HCC patients, with a CD4 T-cell
response expanding in early stages of disease, which is usually
associated with low concentrations of serum AFP, and with
exhaustion of this response in later stages of disease in which there
is a high concentration of serum AFP. This is in accordance with
our earlier reports showing that high concentrations of AFP
suppress immune cell function in vitro (Um et al, 2004), and CD4
T cells isolated from HCC patients with high concentrations of
serum AFP are impaired (Alisa et al, 2005). Our results
demonstrate that Th1 response was mainly detected in HCC
patients with a Child–Pugh A score and Tc1 response was largely
detected in HCC patients with a Child–Pugh B or C score. To our
knowledge, this is the first report suggesting that the balance
between anti-AFP Th1 and Tc1 responses switches to an anti-AFP
Tc1 response as liver cirrhosis progresses. However, it is not clear
why Tc1 response is preferentially expanded in patients with
severe liver cirrhosis.
In conclusion, these results suggest that anti-AFP Th1 responses
are more likely to be present in an early disease stage, whereas
anti-AFP Tc1 responses are more likely to be present when liver
cirrhosis has developed. We believe that the results presented in
this paper will advance our understanding of anti-tumour immune
response in HCC patients and will therefore have important
implications for the development of vaccines or vaccination
strategies.
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